REGENXBIO (RGNX) Stock Forecast, Price & News

REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

Is REGENXBIO a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGENXBIO stock.
View analyst ratings for REGENXBIO or view top-rated stocks.

Are investors shorting REGENXBIO?

REGENXBIO saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 3,660,000 shares, an increase of 20.8% from the April 15th total of 3,030,000 shares. Based on an average daily trading volume, of 414,700 shares, the days-to-cover ratio is currently 8.8 days. Currently, 10.1% of the shares of the stock are sold short.
View REGENXBIO's Short Interest.

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for REGENXBIO.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) announced its earnings results on Tuesday, March, 1st. The biotechnology company reported $6.67 earnings per share for the quarter, topping analysts' consensus estimates of $4.28 by $2.39. The biotechnology company earned $398.66 million during the quarter, compared to the consensus estimate of $255.76 million. REGENXBIO had a net margin of 21.38% and a trailing twelve-month return on equity of 17.92%. The company's quarterly revenue was up 1759.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.24) earnings per share.
View REGENXBIO's earnings history.

What price target have analysts set for RGNX?

7 brokers have issued 12 month price targets for REGENXBIO's shares. Their forecasts range from $17.00 to $82.00. On average, they anticipate REGENXBIO's share price to reach $47.86 in the next twelve months. This suggests a possible upside of 129.6% from the stock's current price.
View analysts' price targets for REGENXBIO or view top-rated stocks among Wall Street analysts.

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:

• Mr. Kenneth T. Mills, Pres, CEO & Director (Age 47, Pay $1.72M)
• Mr. Vittal K. Vasista, Exec. VP & Chief Financial Officer (Age 54, Pay $1.25M)
• Mr. Curran M. Simpson M.S., Exec. VP and Chief Operations & Technology Officer (Age 60, Pay $924.95k)
• Dr. Olivier Danos Ph.D., Exec. VP & Chief Scientific Officer (Age 64, Pay $842.08k)
• Mr. Patrick J. Christmas II, J.D., Exec. VP & Chief Legal Officer (Age 51, Pay $1.11M)
• Ms. Tricia Truehart, VP of Investor Relations & Corp. Communications
• Mr. Andrew Yost, VP of Corp. Devel.
• Ms. Shiva G. Fritsch, Chief People Officer
• Dr. Laura A. Coruzzi J.D., Ph.D., Sr. VP of Intellectual Property (Age 69)
• Mr. Ram Palanki, Sr. VP of Commercial Strategy & Operations

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO CEO Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among REGENXBIO's employees.

Who are some of REGENXBIO's key competitors?

Some companies that are related to REGENXBIO include Abcam (ABCM), Vir Biotechnology (VIR), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), Iovance Biotherapeutics (IOVA), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Krystal Biotech (KRYS), Bavarian Nordic A/S (BVNRY), ImmunityBio (IBRX), Vaxcyte (PCVX) and Valneva (VALN).
View all of RGNX's competitors.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.28%), JPMorgan Chase & Co. (10.95%), Vanguard Group Inc. (9.44%), Dimensional Fund Advisors LP (1.81%), WS Management Lllp (1.10%) and Northern Trust Corp (0.96%). Company insiders that own REGENXBIO stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends for REGENXBIO.

Which major investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Gyon Technologies Capital Management LP, Citigroup Inc., Mirae Asset Global Investments Co. Ltd., Connor Clark & Lunn Investment Management Ltd., SG Americas Securities LLC, Northern Trust Corp, and Metropolitan Life Insurance Co NY. Company insiders that have sold REGENXBIO company stock in the last year include Allan M Fox, Kenneth T Mills, Steve Pakola, and WR Stephens, Iii 2012 Trust.
View insider buying and selling activity for REGENXBIO or view top insider-selling stocks.

Which major investors are buying REGENXBIO stock?

RGNX stock was acquired by a variety of institutional investors in the last quarter, including WS Management Lllp, Assenagon Asset Management S.A., American Century Companies Inc., Jennison Associates LLC, Dimensional Fund Advisors LP, Los Angeles Capital Management LLC, BlackRock Inc., and Russell Investments Group Ltd..
View insider buying and selling activity for REGENXBIO or or view top insider-buying stocks.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $20.84.

How much money does REGENXBIO make?

REGENXBIO has a market capitalization of $898.91 million and generates $470.35 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $2.15 on an earnings per share basis.

How many employees does REGENXBIO have?

REGENXBIO employs 372 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is www.regenxbio.com.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected].